Home » Stocks » TrovaGene

TrovaGene, Inc. (TROV)

May 8, 2020 - Stock symbol was changed to CRDF
Stock Price: $1.19 USD 0.00 (0.00%)
Updated May 7, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 14.18M
Revenue (ttm) 250,632
Net Income (ttm) n/a
Shares Out 13.35M
EPS (ttm) -2.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day May 7, 2020
Last Price $1.19
Previous Close $1.19
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 1.16 - 1.19
Day's Volume 0
52-Week Range 0.70 - 3.46

More Stats

Market Cap 14.18M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.35M
Float 9.35M
EPS (basic) n/a
EPS (diluted) -2.31
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 364,067
Short Ratio 2.00
Short % of Float 3.31%
Beta 1.02
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 56.58
PB Ratio 12.11
Revenue 250,632
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share 0.00
Gross Margin -4,356.03%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -79.89%
ROE -209.72%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$23.00*
Low
23.0
Current: $1.19
High
23.0
Target: 23.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name TrovaGene, Inc.
Country United States
Employees 12
CEO Thomas H. Adams

Stock Information

Ticker Symbol TROV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TROV

Description

Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Trovagene, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.